Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

800 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators. Ariotti S, et al. Among authors: valgimigli m. JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022. Epub 2018 May 24. JACC Cardiovasc Interv. 2018. PMID: 29805112 Free article. Clinical Trial.
Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Marra S, Moretti C, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: valgimigli m. Int J Cardiol. 2009 Sep 11;137(1):16-21. doi: 10.1016/j.ijcard.2008.06.006. Epub 2008 Aug 6. Int J Cardiol. 2009. PMID: 18687481
Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Cruz-Gonzalez I, Marra S, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: valgimigli m. EuroIntervention. 2008 May;4(1):77-83. doi: 10.4244/eijv4i1a14. EuroIntervention. 2008. PMID: 19112783
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.
Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
Onuma Y, Girasis C, Piazza N, Garcia-Garcia HM, Kukreja N, Garg S, Eindhoven J, Cheng JM, Valgimigli M, van Domburg R, Serruys PW; Interventional Cardiologists at Thoraxcenter 2000-2005. Onuma Y, et al. Among authors: valgimigli m. JACC Cardiovasc Interv. 2010 Jun;3(6):584-94. doi: 10.1016/j.jcin.2010.03.017. JACC Cardiovasc Interv. 2010. PMID: 20630451 Free article.
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, Colangelo S, Brugaletta S, Ferrari R, Valgimigli M; 3T/2R Investigators. Campo G, et al. Among authors: valgimigli m. J Am Coll Cardiol. 2010 Oct 26;56(18):1447-55. doi: 10.1016/j.jacc.2010.03.103. J Am Coll Cardiol. 2010. PMID: 20951320 Free article. Clinical Trial.
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, De Cesare N, Colangelo S, Moreno R, Gambetti S, Monti M, Bristot L, Bressers M, Garcia-Garcia HM, Parrinello G, Campo G, Valgimigli M; STRATEGY and MULTISTRATEGY Investigators. Garg S, et al. Among authors: valgimigli m. JACC Cardiovasc Interv. 2011 Jan;4(1):66-75. doi: 10.1016/j.jcin.2010.09.017. JACC Cardiovasc Interv. 2011. PMID: 21251631 Free article.
A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials.
Garg S, Sarno G, Girasis C, Vranckx P, de Vries T, Swart M, Bressers M, Garcia-Garcia HM, van Es GA, Räber L, Campo G, Valgimigli M, Dawkins KD, Windecker S, Serruys PW. Garg S, et al. Among authors: valgimigli m. JACC Cardiovasc Interv. 2011 Jun;4(6):645-53. doi: 10.1016/j.jcin.2011.02.018. JACC Cardiovasc Interv. 2011. PMID: 21700251 Free article.
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Valgimigli M, et al. JACC Cardiovasc Interv. 2012 Mar;5(3):268-77. doi: 10.1016/j.jcin.2012.01.006. JACC Cardiovasc Interv. 2012. PMID: 22440491 Free article. Clinical Trial.
800 results